Last Friday during the after-market session, there was a noticeable increase in the shares of Jaguar Health, Inc. (NASDAQ: JAGX) following the announcement of a noteworthy commercial endeavor. After a normal session fall of -9.75% that left the shares at $4.63, the stock had a comeback of 6.914% after hours, finishing at $4.95.
- Increasing Business Activity
- Addressing Cancer Patients Issues
- Expanding Focus On Cancer Supportive Care
Increasing Business Activity
Jaguar Health (JAGX) shared intention to expand its commercial operations in its main area of expertise, cancer supportive care. Part of that plan, JAGX will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, which runs from May 31 to June 4. During the event, JAGX-division Napo Pharmaceuticals will have Gelclair on display at a booth. Jaguar Health recently obtained the in-license to sell Gelclair, a prescription drug authorized by the FDA for treating oral mucositis. The commercial launch of Gelclair is scheduled to commence in the third quarter of 2024 by Jaguar Health.
Addressing Cancer Patients Issues
JAGX's Gelclair is a barrier-forming protective gel that coats the oral mucosa to assist control and lessen pain. It is used to treat sores in the mouth brought on by a number of illnesses, including oral mucositis and stomatitis. Gelclair does not hurt or function as a numbing agent like other treatments.
Oral mucositis has a substantial financial impact; extra expenses for each patient with head and neck cancer surpass $17,000. With its handy, user-friendly, and clinically proven approach, Gelclair delivers patients quick and durable pain relief that enhances their ability to swallow, eat, drink, speak, and sleep. It also reduces the necessity for parenteral feeding and opiate analgesics.
Expanding Focus On Cancer Supportive Care
At the ASCO Annual Meeting, Jaguar Health will promote awareness among oncologists about Gelclair and the company's growing commitment to cancer supportive care. This commitment is further underscored by Jaguar Health's five-year dedication to studying the prevention of cancer therapy-related diarrhea through the phase 3 OnTarget trial. This trial focuses on over 24 targeted cancer agents that have an incidence of more than 50% diarrhea, with top-line results expected soon.
上週五，在盤後交易時段，捷豹健康公司（納斯達克股票代碼：JAGX）宣佈了一項值得注意的商業舉措後，股價顯著上漲。在正常交易日下跌-9.75％，使股價跌至4.63美元之後，該股盤後回升6.914％，收於4.95美元。
- 增加業務活動
- 解決癌症患者的問題
- 擴大對癌症支持性護理的關注
增加業務活動
捷豹健康（JAGX）共同打算擴大其主要專業領域的商業業務，即癌症支持治療。作爲該計劃的一部分，JAGX將出席5月31日至6月4日舉行的美國臨床腫瘤學會（ASCO）年會。活動期間，JAGX-Division Napo Pharmicals將在展位上展出Gelclair。捷豹健康最近獲得了銷售Gelclair的許可證，這是一種經美國食品藥品管理局批准的用於治療口腔粘膜炎的處方藥。捷豹健康計劃於2024年第三季度開始商業推出Gelclair。
解決癌症患者的問題
JAGX 的 Gelclair 是一種形成屏障的保護凝膠，可覆蓋口腔粘膜，有助於控制和減輕疼痛。它用於治療多種疾病引起的口腔潰瘍，包括口腔粘膜炎和口腔炎。Gelclair不會像其他治療方法那樣造成疼痛或起麻醉劑的作用。
口腔粘膜炎具有重大的財務影響；每位頭頸癌患者的額外費用超過17,000美元。憑藉其方便、用戶友好且經過臨床驗證的方法，Gelclair爲患者提供快速、持久的疼痛緩解，增強他們的吞嚥、進食、飲水、說話和睡眠能力。它還減少了腸外餵養和阿片類鎮痛藥的必要性。
擴大對癌症支持性護理的關注
在ASCO年會上，捷豹健康將提高腫瘤學家對Gelclair以及該公司對癌症支持性護理日益增長的承諾的認識。捷豹健康五年來一直致力於通過3期OnTarget試驗研究癌症療法相關腹瀉的預防，這進一步突顯了這一承諾。該試驗的重點是超過24種腹瀉發病率超過50％的靶向癌症藥物，預計不久將獲得最佳結果。
